Unknown statusInterventionalPhase 1Phase 2Last updated Jun 2, 2021

Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia

Humanized Chimeric Antigen Receptor T Cells Against CD7 for Refractory/Relapsed CD7+ Acute Leukemia

Overview

ClinicalTrials.gov ID: NCT04762485
Lead Sponsor: The First Affiliated Hospital of Soochow UniversityOTHER
Brief Summary: This is a prospective,open-label, single center and single arm phase 1/2 study to evaluate the efficacy and safety of T cells expressing humanized CD7 chimeric antigen receptors treatment for patients with refractory/relapsed CD7 positive acute leukemia.
Study Type

Status

Overall Status: Unknown status
Start Date: Jun 1, 2021Actual
Primary Completion Date: Feb 28, 2023Estimated
Completion Date: Feb 28, 2024Estimated

Study Record Dates

First Submitted: Feb 8, 2021
First Submitted that Met QC Criteria: Feb 17, 2021
First Posted: Feb 21, 2021Actual
Last Update Submitted that Met QC Criteria: Jun 1, 2021
Last Update Posted: Jun 2, 2021Actual
Last Verified: Jan 2021

NCT05059912Unknown status

CD7 CAR T-cell for R/R CD7+ T Cell Lymphoma

NCT05290155Completed

Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies

NCT04785833Unknown status

CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute Leukemia

NCT04599556Unknown status

Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy

NCT07117305Not yet recruiting

CD7 CAR-T Combined With Autologous Hematopoietic Stem Cell Transplantation

NCT05212584Unknown status

CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma